Macro partitioning
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide induce significant lean mass loss (muscle wasting) alongside fat mass loss, which exacerbates sarcopenia and frailty in patients with advanced heart failure.
If you have heart failure and are using GLP-1RAs (like Ozempic or Wegovy), be aware that you will likely lose muscle along with fat. To protect your strength, prioritize high-protein foods and engage in resistance exercise regularly. Discuss these risks with your doctor to balance heart benefits against muscle loss.
While reductions in FM are therapeutically significant, the concurrent loss of LM, primarily muscle, is concerning, as it can contribute to frailty, increased risk of falls, and hospitalization [25,26]. The extent of LM loss (~6.5 kg over ~70 weeks) observed in patients on GLP-1RAs is comparable to the muscle decline experienced over a decade of aging [27–29].
Why this rating
Based on multiple randomized controlled trials (STEP-1, SURMOUNT-1, SUSTAIN-8) cited in the review, though the review itself is a narrative synthesis.
Source
Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure
Winston Wang et al. · Biomedicines · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →